Kidney Week

Kidney Week 2025: Embargo Policy

This American Society of Nephrology (ASN) embargo policy for Kidney Week abstracts (i.e., research abstracts, clinical case reports, late-breaking clinical trials), oral presentations, and posters supersedes all other embargoes. Please adhere to the following embargo policy for ASN Kidney Week abstracts.

Research Abstracts and Clinical Case Reports

• ASN will NOT accept an abstract submission if the abstract:
  1. has already been published by May 21, 2025,
  2. has been accepted for publication by May 21, 2025, or
  3. will have been presented at another meeting or press conference prior to November 6, 2025.
• Abstract notifications will be emailed on August 8, 2025. Between August 8, 2025, and October 16, 2025, accepted abstracts are embargoed, except for abstract titles and authors.
• Accepted Kidney Week abstracts will be posted online on October 17, 2025.
• From October 17, 2025, until time of presentation at Kidney Week, any information beyond what is contained in the four corners of the abstract may not be released until presentation at Kidney Week. With permission of the authors, ASN may selectively lift the embargo prior to presentation at Kidney Week to coincide with Kidney Week press briefing schedules or other press promotions.

Late-Breaking Clinical Trials

• ASN will NOT accept an abstract submission if the late-breaking clinical trial has already been published or has been presented at another meeting or press conference prior to presentation at Kidney Week.
• Late-breaking clinical trial notifications will be emailed on September 30, 2025.
• The titles and authors of accepted late-breaking clinical trials will be posted online on October 17, 2025. Starting on October 17, 2025, an announcement stating that the late-breaking clinical trial has been accepted, along with the title, authors, and date/time of presentation is allowed.
• All accepted late-breaking clinical trial oral presentations and posters are under embargo until time of presentation at Kidney Week. Press releases are not allowed to be issued in advance of the embargo, and embargoed media pitching and interviews are prohibited for all late-breaking clinical trials. If this embargo policy is violated, ASN reserves the right to sanction the violators (authors or press). ASN may, at its discretion, schedule media interviews with authors of select late-breaking clinical trials prior to the embargo lifting.

Violations

Registered media must agree to abide by the Kidney Week embargo policy. Violations of embargoes can result in revocation of press credentials for the year and subsequent year, and immediate removal from Kidney Week.

Simultaneous Publication

Simultaneous publication of late-breaking clinical trials is acceptable and encouraged as long as the embargo policies of ASN and the involved journals are coordinated. If a clinical trial has been submitted and accepted for publication, the Presenting Author is responsible for ensuring that the journal editorial team respects the ASN embargo policy. Publication of a clinical trial, either in print or on a journal website, prior to presentation at ASN Kidney Week violates the ASN embargo policy. If you are interested in simultaneous publication, please notify the journal editorial team, who should then contact ASN Press Officer Christine Feheley at cfeheley@asn-online.org to verify embargo dates/times.

U.S. Securities and Exchange Commission (SEC) Fair Disclosure Requirements

In certain cases, a determination may be made that in order to fulfill the requirements of the SEC or a corresponding regulatory organization in any country where that company's stock is traded, a publicly traded company, before the public release date, must disclose data or information from confidential abstracts. This is generally deemed necessary when it is considered probable that a reasonable investor in the company would regard such data or information as constituting a significant change to the totality of information provided to the investor.

The abstract generally remains eligible to be included in ASN Kidney Week on the condition that the company, prior to the release, submits a letter to ASN signed by the company's legal counsel. The letter must include the title of the abstract, specify the format/nature of the public disclosure, and inform the reader that the information must be publicly disclosed in order to comply with securities laws and that the information disclosed is the minimum necessary to be in compliance with these laws. ASN requirements further specify that the Presenting (First) Author be copied on the request.

Questions? Please contact ASN Press Officer Christine Feheley at cfeheley@asn-online.org.